Status:
UNKNOWN
Application of "I-Anticoagulation"in Patients With Atrial Fibrillation
Lead Sponsor:
RenJi Hospital
Conditions:
Atrial Fibrillation
Anticoagulants
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
The goal of this prospective, multicenter, cluster randomized controlled trial is to assess the effectiveness of a shared decision-making tool, "I-Anticoagulation", for anticoagulation management in A...
Eligibility Criteria
Inclusion
- patients who are 18 years or older and have received a new diagnosis of paroxysmal, persistent, or permanent AF confirmed by electrocardiogram (ECG) or 24-hour Holter monitors
- must be willing to participate in the study and sign the informed consent
Exclusion
- those who are pregnant
- those whohave experienced therapeutic or subtherapeutic bleeding complications in the last 6 months
- those who have severe renal insufficiency (creatinine clearance rate, CrCl ≤ 20 ml/min)
- those who have severe hepatic insufficiency (Child-Pugh ≥ 10 points)
- those who have severe heart failure (cardiac function New York Heart Association, NYHA grade IV and above)
- those who have severe infection and respiratory failure
- those who are unable to comply with the study requirements.
Key Trial Info
Start Date :
November 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
440 Patients enrolled
Trial Details
Trial ID
NCT06137794
Start Date
November 15 2023
End Date
June 30 2025
Last Update
November 18 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.